We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New 'Protein Nano-Switch' Method Paves Way for Faster, More Accurate Diagnostic Tests

By LabMedica International staff writers
Posted on 02 Aug 2023

Presently, 'point of care' diagnostic tests that offer results on the spot, such as those for blood sugar, pregnancy, and COVID-19, utilize protein-sensing systems to detect sugar, pregnancy hormones, and COVID-19 proteins. More...

However, these tests make up only a small part of the requirements in a patient-centric healthcare model. The creation of new sensing systems is a demanding and lengthy task that involves significant trial and error. Researchers have now developed a new 'protein nano-switch' technique that significantly accelerates the development of similar diagnostic tests by reducing the required time and boosting success rates.

A multidisciplinary research team that included scientists from Queensland University of Technology (QUT, Brisbane, Australia) has developed an approach for designing molecular ON-OFF switches based on proteins that can be applied in numerous biotechnological, biomedical, and bioengineering settings. This innovative method which allows researchers to develop more rapid and accurate diagnostic tests involves using modified proteins to act like ON/OFF switches in response to specific targets. The key advantage is that the system is modular, much like building with Lego blocks, allowing for easy replacement of parts to target different elements—such as a different drug or a medical biomarker.

The new protein-engineering technology offers a unique way to create lab tests. It offers the potential to construct various diagnostic and analytic tests with a broad array of possible applications, including human and animal health diagnostics. The researchers demonstrated their technology by focusing on a cancer chemotherapy drug that is toxic and must be frequently measured to ensure patient safety. The sensor they designed for this drug uses a color change to identify and measure the drug. The next stage would involve testing the sensor for clinical use approval. The researchers intend to standardize and scale this approach and begin creating more complex subsystems. According to the researchers, there are two potential paths for future work.

"One is to develop computer models that allow us to design and build the switches even more rapidly and precisely," said Professor Kirill Alexandrov, of the QUT School of Biology and Environmental Science. "The other is to demonstrate the scale and potential of the technology by building many switches for different diagnostic applications."

Related Links:
QUT 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Thyroid Test
Anti-Thyroid EIA Test
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.